350 results about "Glycolipid" patented technology

The application belongs to the field of intestinal microbiology, and discloses a new mucinophilic Akkermansia with improved obesity and glycolipid metabolism, wherein the mucinophilic Akkermansia strain is Akk-101 and AMY001. The preservation number of Akk-101 is CGMCC No. 40786, and the preservation number of AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains in the application are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have better acid-base tolerance and colonization capacity than the standard strains, can more effectively inhibit the accumulation of liver cell lipids, reduce the fat deposition in nematodes, and have the effects of weight loss and improvement of glycolipid metabolism, so that related products can be effectively developed based on the strains.

The invention provides an amino acid frosted cleaning composition as well as a preparation method and application thereof. The amino acid frosted cleaning composition comprises a surfactant, an amino acid composition, a thickening agent, a humectant, an antioxidant, a pH regulator and water, the surfactant is a combination of cocoyl glycinate, cocamidopropyl hydroxy sulfobetaine, sodium cocoyl methyl taurine taurate, sulfonic acid hydroxypropyl ester lauryl glucoside cross-linked polymer sodium and glycolipid. According to the invention, a mild surfactant system with amino acid as a main component is adopted, so that the shampoo has rich and fine foam, quick foaming performance and easy washing performance, and the skin feeling is smooth and soft after washing. In addition, the system contains suspended crystal frosted particles formed by self-assembly of the amino acid composition, the appearance is novel, the better efficacy performance is achieved, and meanwhile the cleaning effect and the use comfort are improved.

The invention discloses a medicinal and edible homologous compound based on probiotic fermentation synergy and application of the medicinal and edible homologous compound in blood sugar regulation and control, and belongs to the technical field of microorganisms and fermentation engineering. The preparation method comprises the following steps: respectively carrying out two-stage fermentation on aloe, mulberry leaves and liquorice by utilizing saccharomyces cerevisiae BLCC4-0032 and plant lactobacillus DFR-1, so as to obtain a fermentation mixture; the preparation method comprises the following steps: fermenting a fermentation mixture, adding balsam pear peptide into the fermentation mixture to obtain a medicinal and edible compound, forming a metabolic closed loop, and cooperatively regulating a'blood sugar-liver-intestinal flora axis', thereby providing a new solution for diabetes intervention, and opening up a new path for preventing non-alcoholic fatty liver and intestinal inflammation caused by glucose and lipid metabolism disorder.

The invention discloses a method for treating piglet damp-heat diarrhea through multi-omics combined analysis. According to the method, faeces metabonomics, intestinal transcriptomics and intestinal flora 16s analysis are adopted, transcriptome data, metabolome data and intestinal flora data are screened according to a prime difference standard, then transcriptomics of a model group and a control group, faeces metabonomics and intestinal flora are subjected to conjoint analysis, an intersection is taken, and the faeces metabonomics of the model group and the control group, the faeces metabonomics of the model group and the control group and the intestinal flora of the model group and the control group are subjected carrying out conjoint analysis on transcriptomics of the Model group and HQ-M, faeces metabonomics and intestinal flora, and then taking an intersection; the method comprises the following steps of: selecting a plurality of metabolites and florae from a plurality of intestinal florae, respectively obtaining intersections, screening related genes, searching gene FPKM expression quantity in transcriptomics, and screening corresponding metabolites and florae in metabonomics and intestinal florae to obtain a gene-flora-metabolite related network diagram. Multi-omics combined analysis shows that the piglet diarrhea due to damp-heat is mainly manifested by inflammation and glucose and lipid metabolism disorder.

The present application relates to use of Ligilactobacillus salivarius in preparing a drug for preventing and / or treating diseases associated with overweight and / or obesity . The strain can inhibit the weight growth of a high-fat diet-induced obesity model mouse, reduce the blood lipid level of the high-fat diet-induced obesity model mouse, improve the liver injury index of the high-fat diet-induced obesity model mouse, reduce the area of white adipose cells of the high-fat diet-induced obesity model mouse, improve the colon GLP-1 level of the high-fat diet-induced obesity model mouse, improve the intestinal flora imbalance of the high-fat diet-induced obesity model mouse, and improve the liver glycolipid metabolism of the high-fat diet-induced obesity model mouse; and reduce the waist circumference, hip circumference, body fat mass, BMI, and weight of overweight and overweight and / or obesity volunteers, and maintain the muscle content, promoting overweight and overweight and / or obesity people to carry out safe, effective, and sustainable weight management.

The invention belongs to the technical field of cosmetics, and particularly relates to a cosmetic delivery system based on a natural wall material, a preparation method and application. The cosmetic delivery system is of a core-shell structure, a core is a cosmetic active component, and a shell layer is a composite polymer gel network of sodium alginate, sophorolipid and cellulose. The natural polysaccharide composite wall material is green and safe, has good biocompatibility and strong compatibility with cosmetic formulas, and does not irritate the skin. The delivery system can effectively protect cosmetic active ingredients from being damaged by illumination and oxygen, and the storage stability of the active ingredients is remarkably improved; meanwhile, slow release and targeted transdermal absorption of active ingredients are realized, and the bioavailability is improved.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis) capable of relieving liver injury and regulating glycolipid metabolism and application of the bifidobacterium animalis subsp. Lactis. The preservation number of the bifidobacterium animalis subsp. Lactis is CGMCC No.31656, and the bifidobacterium animalis subsp. Lactis can effectively reduce blood sugar and blood fat of diabetic mice and relieve insulin resistance and has the capacity of relieving diabetic cardiomyopathy. The strain has wide application prospects in preparation of drugs for treating diabetes mellitus, liver injury and glycolipid metabolism.

The invention discloses a lactobacillus rhamnosus HX-4F3 strain and application thereof, and belongs to the technical field of biology. The lactobacillus rhamnosus HX-4F3 disclosed by the invention is preserved in the China Center for Type Culture Collection, and the preservation number of the lactobacillus rhamnosus HX-4F3 is CCTCC (China Center for Type Culture Collection) NO: M 20251454. The invention discloses an application of a strain HX-4F3 in preparation of drugs or food for lowering lipid or / and blood sugar. The invention also discloses application of the compound in preparation of functional food or / and medicines for preventing or / and treating metabolic diseases. The invention also discloses a composition for lowering lipid or / and blood sugar, which comprises a live bacterium of the strain HX-4F3 or freeze-dried powder, a spore preparation, a metabolic supernatant or an inactivated bacterium of the strain HX-4F3, and a pharmaceutically or food acceptable carrier. According to the lactobacillus rhamnosus HX-4F3 provided by the invention, the glucose and lipid metabolism disorder can be remarkably improved through a multiple synergistic mechanism, and the glucose and lipid metabolism disorder can be remarkably improved through the lactobacillus rhamnosus HX-4F3.

The present application relates to the technical field of genetic engineering, and in particular to a high-yield sophorolipid gene knockout engineering bacterium, a construction method thereof and an application, the engineering bacterium taking Bombus bornensis Candida as a starting strain, and using a gF-Hph-gR nucleotide sequence to replace a gene sequence seq2 in a sophorolipid synthesis path for regulating a lactonization reaction ， The gF-Hph-gR nucleotide sequence is SEQ ID No. 1, and the seq2 gene sequence is SEQ ID No. 2. The method provided by the present application uses fusion PCR to construct a seq2 gene knockout box with a resistance screening marker, and the shortest time required is 1 day, which provides a new way for efficiently constructing a sophorolipid production engineering strain. The high-yield sophorolipid gene knockout strain provided by the present application lays a foundation for large-scale industrial production of sophorolipid and meets market demand, and has a wide application prospect, economic value and social benefit.

The invention relates to the technical field of biological medicines, in particular to application of Amomum villosum Lour. In preparation of products for preventing and / or improving symptoms related to obesity and glucose and lipid metabolism disorder. The symptoms comprise hyperglycemia level, cardiovascular and cerebrovascular diseases, cognitive impairment and the like. The result shows that the fructus amomi can effectively reduce the blood sugar level, obviously inhibit the rise of low-density lipoprotein, improve the cognitive function and regulate the lipid metabolism balance. Based on good glycolipid metabolism regulation activity, fructus amomi can be used for improving hyperglycemia, cardiovascular and cerebrovascular diseases, related cognitive function decline and other symptoms caused by abnormal glycolipid metabolism.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention provides a drug-loaded sophorolipid microsphere, a preparation method thereof and application of the drug-loaded sophorolipid microsphere in preparation of a bionic cartilage scaffold. The preparation method of the drug-loaded sophorolipid microspheres comprises the following steps: (1) preparing a drug-containing sophorolipid solution; (2) preparing multiple emulsion; and (3) adding a horse radish peroxidase solution into the multiple emulsion for reaction to obtain the drug-loaded sophorolipid microspheres. The bionic cartilage scaffold sequentially comprises a bone layer, a transition layer and a cartilage layer from bottom to top, the bone layer is a cross-linked compound of nano-hydroxyapatite and drug-loaded sophorolipid microspheres; the transition layer is a physical mixture of nano-hydroxyapatite and drug-loaded sophorolipid microspheres; the cartilage layer is drug-loaded sophorolipid microspheres. The drug-loaded sophorolipid microspheres disclosed by the invention have good biocompatibility, excellent biocompatibility and good mechanical properties. The bionic cartilage scaffold utilizes the characteristics of the nHA and the drug-loaded sophorolipid microspheres to form a unique network structure, so that material failure caused by mechanical mismatching is avoided.

The invention discloses a functional lipid compound for nano-liposome wrapping and a preparation method, and relates to the technical field of functional lipid compounds, the functional lipid compound comprises (a) a polyphenol-lipid covalent conjugate which is composed of a polyphenol active unit selected from curcumin, dihydroquercetin or derivatives thereof, and (b) a lipid covalent conjugate which is composed of a polyphenols active unit selected from curcumin, dihydroquercetin or derivatives thereof and a polyphenols active unit selected from curcumin, dihydroquercetin or derivatives thereof; the conjugate is covalently linked to a phosphatidyl ethanolamine or cholesterol skeleton through a cleavable linking group, and the conjugate can be integrated into a nano-liposome membrane and has the functions of structural support and biological activity; (b) a microenvironment-responsive functional phospholipid, which is a phospholipid derivative having a functional group responsive to an inflammatory microenvironment specific stimulus modified on a hydrophilic head group or a hydrophobic chain of a phospholipid molecule, the specific stimulus being selected from local pH < = 6.5, reactive oxygen species (ROS) concentration > = 10 [mu] M or matrix metalloproteinase MMP-2 / 9 overexpression; and (c) a bionic exosome membrane lipid component, wherein the bionic exosome membrane lipid component comprises sphingosine-based glycolipid or sulfated cholesterol separated from the plant-derived exosome.

The application discloses a polypeptide composition for treating obesity and related metabolic diseases and application thereof. The polypeptide composition comprises polypeptide 1 and polypeptide 2, wherein the amino acid sequence of the polypeptide 1 is shown as SEQ ID NO. 1, can be specifically combined with the CD105 receptor on the surface of MSCs and the AdipoR1 receptor of adipocytes; the amino acid sequence of the polypeptide 2 is shown as SEQ ID NO. 2, can target adipose tissue and regulate glycolipid metabolism. The polypeptide composition is combined with fat-derived mesenchymal stem cells (MSCs) and applied to a high-fat-diet obese mouse model, and the results show that the composition has a significant synergistic effect in reducing body fat, improving the morphology of adipose tissue, regulating serum metabolic factors and inflammatory factors, and has no obvious organ toxicity. The application provides a new effective strategy and a safe and reliable pharmaceutical composition for treating obesity and related metabolic diseases.

The invention belongs to the technical field of biology, and discloses an aleurites latifolia strain for high yield of osmanthus fragrans glycolipid and an application of the aleurites latifolia strain in production of osmanthus fragrans glycolipid, the name of the strain is HT353, the classification name is aleurites latifolia, the preservation number is CGMCC NO.41864, the preservation date is China General Microbiological Culture Collection Center on March 19, 2025, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC NO.41864, the preservation number is CGMCC NO.41864, the preservation number is CGMCC NO.41864, and the preservation number is CGMCC NO.41864. The preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. In order to solve the problem of low yield of the mandarin fungus glycolipid of the mandarin fungus, the transformation process of the mandarin fungus strain is accelerated. According to the invention, spaceflight breeding is utilized to obtain the auricularia coralloides strain with the yield of the glycolipid of the auricularia coralloides of 2.9 g / L, the biomass of 8.02 g / L and the growth speed of 1.19 mm.d <-1 >, which are respectively increased by 66.29%, 3.6% and 10.19% compared with the original strain.

The invention provides an abnormal glycolipid metabolism risk dynamic assessment system based on SNP and gene analysis and application of the system in neuropsychiatric drug therapy, and belongs to the technical field of biological medicine. The system disclosed by the invention contains the primer probe group for detecting the metabolic influence of the antipsychotic drug, so that specific amplification detection of a specific SNP site can be realized, clinical guidance is targeted, and abnormal glucose and lipid metabolism and significant change of body weight are avoided. According to the method, glucose and lipid metabolism and effect target gene detection products are adopted for detection, a detection result is evaluated and interpreted through a glucose and lipid metabolism abnormal risk dynamic evaluation algorithm, retrospective investigation and actual case observation are combined, the detection result is good in sensitivity, high in accuracy and high in practicability, sampling is convenient, the evaluation algorithm is professional and reasonable, and the method is suitable for popularization and application. Results are easy to understand and easy to popularize and use.

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.

This invention relates to the field of semiconductor cleaning technology and discloses a cleaning agent for semiconductor silicon wafers and its preparation method. This cleaning agent aims to solve the problem that traditional strong alkaline or phosphate-based wet electronic chemical cleaning agents easily corrode the silicon wafer surface, damage the crystal lattice, and thus affect electrical performance. This cleaning agent utilizes a multi-component synergistic effect: a surfactant system composed of alkyl glycosides and sophorolipids enhances particle wetting and stripping; lipase and silicon-pharmacoprotein precisely catalyze the removal of specific contaminants; sodium gluconate complexes metal ions; gelatin-polyacrylamide copolymer disperses contaminants to prevent secondary contamination; glycerol and trehalose maintain enzyme activity; and ultrapure water ensures the system meets the electronic-grade purity standards for wet electronic chemicals. Overall, it avoids strong alkaline corrosion, maintains the integrity of the silicon wafer lattice, and improves particle removal efficiency, meeting the high standards required for wet electronic chemical-based silicon wafer cleaning agents in advanced processes.

The application discloses a use of a pharmaceutical composition of a phenolic acid compound and probiotics, and particularly relates to a combination of chlorogenic acid and lactobacillus reuteri. The combination of chlorogenic acid and lactobacillus reuteri can improve glycolipid metabolic disorder, improve cognitive dysfunction, emotional disorder and delay aging, and can be used for preparing a medicine for treating metabolic disorder combined with neuropsychiatric diseases.

The invention provides a low-GI liquid dietary fiber composition, an oral gel and a preparation method and application thereof, and belongs to the technical field of biology. The liquid dietary fiber composition comprises the following raw materials in parts by weight: 4-10 parts of bitter gourds, 7-15 parts of konjac powder, 2-6 parts of white kidney beans, 15-25 parts of barley, 3-9 parts of apples, 3-9 parts of passion flowers, 5-11 parts of blueberry concentrated juice and 4-6 parts of fructo-oligosaccharide. The liquid dietary fiber composition prepared from the raw materials has obvious effects of treating and / or preventing intestinal diseases and blocking glycolipid absorption.

TITLE: Coacervate Cleansing Composition with Mineral Particle. The disclosure relates to compositions comprising (a) at least one amphoteric surfactant, (b) at least one glycolipid, (c) at least one cationic polymer at a concentration of approximately 0.05% to approximately 2%; (d) at least one mineral particle, and (e) at least one cosmetically acceptable solvent, in which the cleansing system is substantially free of phenoxyethanol, and in which the pH of the composition is between approximately 4 and approximately 8, and in which the weight ratio of a to b is approximately 0.4 to approximately 4, and in which the combined concentration of a and b is approximately 10% to approximately 20% of the total weight of the composition. The compositions may be used as rinse-off compositions to cleanse the skin and deposit mineral particles. Figure for abstract: none

The invention discloses a method for improving the quality of ganoderma lucidum mushroom residues through synergistic fermentation of bacteria and enzymes and application of the method. According to the method disclosed by the invention, cellulase, beta-galactosidase and xylanase with proper concentrations and lactobacillus plantarum, bacillus subtilis and saccharomyces cerevisiae with proper proportions are adopted, and enzymes and bacteria are mutually cooperated, so that the characteristics of the raw materials are well balanced, the finally prepared ganoderma lucidum mushroom bran is high in protein content and low in fiber content, and the nutritional value of a feed is improved; the total amount of amino acids and essential amino acids are remarkably increased, and the feed protein quality can be improved; the rumen dry matter digestibility and energy metabolites are remarkably improved, and ruminant absorption and utilization are facilitated; the ganoderma lucidum mushroom bran fermented feed is added into the daily ration, so that the daily gain, the carcass rate and the dressing percentage of fed animals can be remarkably improved, the levels of serum GLU, TG, ALT and AST are reduced, the expression of key inflammatory cytokines (IL-1beta and IL-6) is inhibited, and the ganoderma lucidum mushroom bran fermented feed has the comprehensive effects of regulating glycolipid metabolism and relieving liver load and systemic inflammation, so that the immune function of animal bodies is improved.

Provided is a yeast mutant strain having high glycolipid productivity. A yeast mutant strain in which the expression of a polypeptide comprising an amino acid sequence represented by SEQ ID NO: 2 or an amino acid sequence being at least 90% identical to the amino acid sequence represented by SEQ ID NO: 2 is suppressed or inactivated.

The present invention relates to mutants of the bumblebee Yarrowia SBLE enzyme having modulated transesterification and / or esterification activity compared to the bumblebee Yarrowia SBLE enzyme, and to homologues of the bumblebee Yarrowia SBLE enzyme, such as the C. bogoriensis LE enzyme, the B. batistae LE enzyme and the R. riograndensis LE enzyme, having transesterification and esterification activity on bolaform glycolipids. The present invention also provides genetically modified yeast strains comprising a mutant LE enzyme or a bumblebee Yarrowia SBLE enzyme homologue of the present invention. The present invention further provides the use and methods of the mutant LE enzymes, the bumblebee Yarrowia SBLE enzyme homologues and the modified yeast strains of the present invention for the production of acidic glycolipids, lactone-form glycolipids and / or glycolipid oligomers / polymers / esters. The present invention also provides the three-dimensional structure of the bumblebee Yarrowia SBLE enzyme and its use for the design of mutants having modulated hydrolysis and / or transesterification activity.

The invention relates to the non-therapeutic nutricosmetic use of a composition in a form suitable for oral administration comprising a wheat extract in a physiologically acceptable medium. The invention is characterized in that the wheat extract contains 35-40% of triglycerides and diglycerides, 20-30% of glycolipids, 7-10% of phospholipids and 2-4% of ceramides and glycosylceramides, by weight relative to the total weight of the extract, and is used to reduce excessive sebum secretion in the skin of the face.

COACERVAT CLEANSING COMPOSITION WITH ACNE TREATMENT ACTIVE The disclosure relates to compositions comprising (a) at least one amphoteric surfactant, (b) at least one glycolipid, (c) at least one cationic polymer at a concentration of approximately 0.05% to approximately 2%; (d) at least one acne treatment active, and (e) at least one cosmetically acceptable solvent, in which the cleansing system is substantially free of phenoxyethanol, and in which the pH of the composition is between approximately 4 and approximately 8, and in which the weight ratio of a to b is approximately 0.4 to approximately 4, and in which the combined concentration of a and b is approximately 10% to approximately 20% of the total weight of the composition. The compositions may be used as rinse-off compositions to cleanse the skin and deposit acne treatment actives. Figure for the abstract: none

The invention provides application of loranthus parasiticus in preparation of a lipid-lowering medicine. The application has the advantages that the loranthus parasiticus extract can effectively improve HFD-induced obesity and glucose and lipid metabolism disorder; the loranthus parasiticus extract can relieve adipose tissue enlargement and liver fatty degeneration.

The present invention relates to a method for producing glycolipids in recombinant host cells and to a novel glycolipid obtained by said method as well as nucleic acid molecules used in this method.

The present disclosure provides compositions and dosage forms thereof, wherein the compositions comprise hyaluronic acid and a lipid extract comprising a ceramide and glycolipid. The present disclosure further provides methods for improving a skin property in a subject by administering the composition or dosage form to the subject.

This disclosure relates to antimicrobial compositions comprising at least one cationic antimicrobial substance and at least one acidic glycolipid, as well as the use of such compositions in product formulations, particularly anionic formulations such as personal care, home care, and other product formulations.